Search
for
Sort by
Research 331–360 of 531
- Understanding the Role of Type I Interferons in Cutaneous Lupus and Dermatomyositis: Toward Better Therapeutics
- Efficacy and Potential Mechanisms of Naringin in Atopic Dermatitis
- Ex Vivo Treatment with Allogenic Mesenchymal Stem Cells of a Healthy Donor on Peripheral Blood Mononuclear Cells of Patients with Severe Alopecia Areata: Targeting Dysregulated T Cells and the Acquisition of Immunotolerance
- Astilbin Activates the Reactive Oxidative Species/PPARγ Pathway to Suppress Effector CD4+ T Cell Activities via Direct Binding With Cytochrome P450 1B1
- The potential of regulatory T cell-based therapies for alopecia areata
- Rationale and Design of a Novel, Phase 3, External and Synthetic Placebo-Controlled Clinical Trial of Ritlecitinib 50 mg and 100 mg for Alopecia Areata
- Ritlecitinib in severe alopecia areata: a profile of its use
- Long-Term Efficacy and Safety of Ritlecitinib in Adults and Adolescents with Alopecia Areata: 3-Year Results from the ALLEGRO Phase 2b/3 and ALLEGRO-LT Phase 3 Clinical Studies
- Responses to Tetanus and Meningococcal Vaccines in Patients with Alopecia Areata Treated with Ritlecitinib
- Impact of Previous Alopecia Areata Treatment on Efficacy Responses up to Week 48 Following Ritlecitinib Treatment: A Post Hoc Analysis
- Extensive alopecia areata is reversed by IL-12/IL-23p40 cytokine antagonism
- Case Series and Literature Review on Tofacitinib for Treating Severe Alopecia Areata
- Effect of tofacitinib on the expression of noggin/BMP-4 and hair growth stimulation in mice
- Long-term Efficacy and Safety of Ritlecitinib in Adults and Adolescents with Alopecia Areata: 3-year Results from the ALLEGRO-LT Phase 3, Open-label Study
- New therapies for alopecia areata
- Prediction of Long-term Scalp Hair Regrowth at 24 Months in Patients with Alopecia Areata Receiving Ritlecitinib Treatment in the ALLEGRO Clinical Trial Program
- 1323 The effects of 3-OH of kaempferol on interfollicular epidermal stem cell fate
- 1324 Impairment of hair-inducing capacity of 3D-cultured human dermal papilla cells by the ablation of STAT5
- 1327 Effect of ginsenoside Rd on dermal epidermal junction in fibroblast
- ORAL TOFACITINIB IN MODERATE AND SEVERE ALOPECIA AREATA: CASE SERIES OF 14 PATIENTS
- Experience with oral tofacitinib in severe alopecia areata with different clinical responses
- Efficacy of tofacitinib in treatment of alopecia universalis in two patients
- 3-Deoxysappanchalcone Promotes Proliferation of Human Hair Follicle Dermal Papilla Cells and Hair Growth in C57BL/6 Mice by Modulating WNT/β-Catenin and STAT Signaling
- Case Report: Successful treatment of pediatric alopecia universalis with ritlecitinib after failure of baricitinib
- A consensus-based treatment algorithm for alopecia areata in adolescents and adults: integrating severity, quality of life, and disease dynamics
- Exploring the Drug Repurposing Versatility of Valproic Acid as a Multifunctional Regulator of Innate and Adaptive Immune Cells
- MSC-EVs and UCB-EVs promote skin wound healing and spatial transcriptome analysis
- Sublingual tofacitinib for alopecia areata: a roll‐over pilot clinical trial and analysis of pharmacokinetics
- Experience with oral tofacitinib in two adolescents and seven adults with alopecia areata
- Evidence Synthesis Gone Awry: The Perils of Aggregating Ineffective or Unsafe Doses in Alopecia Areata Reviews